- Quest Diagnostics ( NYSE: DGX ) is trading 5.6% higher after it raised its guidance and beat revenue, profit estimates as its business rebounding in August and September from the softer volume trends seen earlier in the year.
- The company now expects 2022 net revenue between $9.72B to $9.86B from prior outlook of $9.50B to $9.75B, ahead of analyst estimate of $9.67B.
- 2022 adjusted diluted EPS expected to be between $9.75 and $9.95 from prior outlook of $9.55 and $9.95, and ahead of estimates of $9.68 consensus.
- The company expects COVID-19 testing revenues to be between $1.34B to $1.41B from prior outlook of $1.15B to $1.30B.
- Revenue fell 10.1% Y/Y to $2.49B, but beat estimates by $150M.
- Q3 Non-GAAP EPS of $2.36 beats by $0.18.
For further details see:
Quest Diagnostics rises on strong Q3 result, raises 2022 forecast